A serology test or antibody test detects the presence of antibodies like Immunoglobulin G (IgG) and Immunoglobulin M (IgM) in the blood from the body’s adaptive immune response to an infection.
An antibody test does not detect the virus itself. In the early days of an infection when the body’s adaptive immune response is still building, antibodies may not be detected. For this reason, an Antibody test cannot be used for diagnosing current COVID-19 or to exclude acute COVID-19 infection.
However, serology tests play a role in the fight against COVID-19 by helping health care professionals identify individuals who may have developed an adaptive immune response to SARS-CoV-2 or to assess the protection from SARS-COV2 vaccine.
- Anti S protein Qualitative IgG and IgM antibody
- Anti-N-protein Qualitative IgG and IgM antibody
SARS COV2-Neutralizing antibody test by automated ELISA system
We use the cPass™ neutralizing antibody technology from GenScript for this test.
The cPass™ technology allows for the rapid detection of total neutralizing antibodies (NAbs) in a sample by mimicking the interaction between the virus and the host cell. In order for a virus to infect a host cell, a viral receptor binding protein (RBD) first needs to interact with the host cell’s membrane receptor protein (ACE2).
The virus-host interaction and subsequent viral infection of the host cell leads to the activation of an individual’s immune response which generates a population of antibodies against the virus. Some of these antibodies can bind to the virus, but not necessarily block viral infection. Other antibodies can bind to the RBD in a way that blocks the interaction with the ACE2 receptor. The cPass™ technology helps to distinguish whether a sample contains NAbs that may specifically block the interaction and therefore the viral entry into the host cell.